
Izvēlieties etiķeti
redzama tieši uz flakona7 laboratorijas ziņojumi
PDF- Pārbaudīts
- Retatrutide 10mg
- Laboratorija
- Analiza Białek
- Datums
- November 2026
- Rezultāts
- 99% purity (10.37 mg measured)
- Endotoksīni
- 5.54 EU/vial
- Pasūtījuma nr.
- Parole
PDF- Pārbaudīts
- Retatrutide 15mg
- Laboratorija
- Analiza Białek
- Datums
- November 2026
- Rezultāts
- 99% purity (16.53 mg measured)
- Endotoksīni
- 5.91 EU/vial
- Pasūtījuma nr.
- Parole
PDF- Pārbaudīts
- Retatrutide 30mg
- Laboratorija
- Analiza Białek
- Datums
- November 2026
- Rezultāts
- 99% purity (31.88 mg measured)
- Endotoksīni
- 6.29 EU/vial
- Pasūtījuma nr.
- Parole
PDF- Pārbaudīts
- Retatrutide 40mg
- Laboratorija
- Analiza Białek
- Datums
- November 2026
- Rezultāts
- 99% purity (40.92 mg measured)
- Endotoksīni
- 6.82 EU/vial
- Pasūtījuma nr.
- Parole
PDF- Pārbaudīts
- Retatrutide 60mg
- Laboratorija
- Analiza Białek
- Datums
- November 2026
- Rezultāts
- 99% purity (60.10 mg measured)
- Endotoksīni
- 7.73 EU/vial
- Pasūtījuma nr.
- Parole
PDF- Pārbaudīts
- Retatrutide 20mg
- Laboratorija
- Analiza Białek
- Datums
- October 2026
- Rezultāts
- 99% purity (23.28 mg measured)
- Endotoksīni
- 6.15 EU/vial
- Pasūtījuma nr.
- Parole
PDF- Pārbaudīts
- Retatrutide 5mg
- Laboratorija
- Analiza Białek
- Datums
- July 2026
- Rezultāts
- 99% purity (5.28 mg measured)
- Pasūtījuma nr.
- Parole
Neatkarīgi pārbaudīts, ar paroli pārbaudāms tieši laboratorijā.
Retatrutide
GLP-1
- Laboratorijā pārbaudīts · 99% tīrība
- Sūtām no Vācijas
Pasūtījums
- DHL ar izsekošanu
- Diskrēts iepakojums
4.6 no 5 Trustpilot73 atsauksmes
Meklēts arī kā: Retatrutid · Reta · LY3437943
Īsumā
Retatrutide skaitļos
Galvenie rādītāji no mūsu leksikona. Velciet punktu pa līkni, lai redzētu, cik daudz paliek pēc vienas devas, pēc aprēķina.
Pilns leksikona ierakstsHow long does it stay in the body?
Share left after one dose, calculated with a half-life of ~6 days
Simplified model without an absorption phase, half-life from the TPD lexicon.
Half-life
~6days
- Class
- Triple agonistGLP-1 / GIP / glucagon
- Frequency
- Once weeklysubcutaneous
- Form
- Lyophilised powderreconstituted with BAC water
- Sizes
- 5 to 60 mg11 sizes in the shop
What studies show
All 10 sources in the lexicon- up to25 %
Phase 3 trial TRIUMPH-1 in obesity (up to 25% weight reduction at 80 weeks) (opens in a new tab)
Jastreboff et al., New England Journal of Medicine, 2026 - up to18.8 %Bellido et al., The Lancet, 2026
- up to~24 %
Phase 2 study in obesity (up to ~24% weight reduction at 48 weeks) (opens in a new tab)
Jastreboff et al., New England Journal of Medicine, 2023
Zināšanas
Viss par Retatrutide
Detalizēta informācija drīzumā.
Dozēšana
Ielādē dozēšanas informāciju …
Noderēs
Kas jums vēl būs vajadzīgs
Bakteriostatiskais ūdens tiek automātiski pievienots grozam. Šļirces un salvetes - ar vienu klikšķi.
Insulīna šļirces
10 gab. · 5.50 €
Spirta salvetes
50 gab. · 10 €
Cik daudz ūdens?
Vienības uz šļirces jūsu flakona izmēram.
Atvērt kalkulatoru →Is Retatrutide approved?
No, as of 25 October 2026 there is no approval. Retatrutide is in phase 3: 14 phase 3 trials are listed on ClinicalTrials.gov, five of them completed. The first phase 3 results were published in 2026.
How does Retatrutide differ from Tirzepatide and Semaglutide?
The number of receptors. Semaglutide acts only on the GLP-1 receptor, Tirzepatide on GLP-1 and GIP. Retatrutide also targets the glucagon receptor. In animal models this added higher energy expenditure. A head-to-head trial against Tirzepatide is still running (TRIUMPH-5).
What did the phase 3 trials show?
In TRIUMPH-1 (obesity without diabetes) weight fell by 25.0 percent on average after 80 weeks at the highest study dose, by 3.9 percent on placebo. In TRIUMPH-2 (with type 2 diabetes) it was 18.8 versus 5.1 percent. In TRANSCEND-T2D-1 long-term blood sugar (HbA1c) fell by up to 1.94 percentage points in 40 weeks.
What happens to liver fat?
In a substudy with fatty liver (MASLD) liver fat fell by about 81 to 82 percent after 24 weeks in the two higher levels. 86 percent reached normal liver fat below 5 percent at the highest level. A large phase 3 trial on liver disease runs until 2030.
Which side effects were seen?
Most often gastrointestinal effects such as nausea and diarrhoea, depending on the dose. In TRIUMPH-2 abnormal skin sensations (dysaesthesia) and low blood pressure occurred more often than on placebo. In the phase 2 trial heart rate rose in a dose-dependent way, most around week 24.
Which trials are still running?
Nine phase 3 trials are not finished yet. The largest: TRIUMPH-OUTCOMES on heart and kidney events with about 10,000 participants (planned end 2029) and SYNERGY-Outcomes on fatty liver (2030). The comparison with Tirzepatide (TRIUMPH-5) is due to reach its primary endpoint in November 2026.
Salīdzinājumi
Kā tas atšķiras
Saistītie
Saistītie produkti
Tirzepatide
Peptīdi · GLP-1 un tauku zudums GLP-1 un tauku zudums
10 izmēri
Laboratorijā pārbaudīts
= no 10 €/flakons
Semaglutide
Peptīdi · GLP-1 un tauku zudums GLP-1 un tauku zudums
6 izmēri
Laboratorijā pārbaudīts
= no 10 €/flakons
Mazdutide
Peptīdi · GLP-1 un tauku zudums GLP-1 un tauku zudums
2 izmēri
= no 32 €/flakons
Survodutide
Peptīdi · GLP-1 un tauku zudums GLP-1 un tauku zudums
1 izmērs
= 60.8 €/flakons
Retatrutide

